New Study Identifies Folate Receptor as Key to Colorectal Cancer Immunotherapy Resistance in Mice
A new study has revealed that a receptor for folate, Folate Receptor α (FOLR1), plays a critical role in enabling colorectal cancer (CRC) to evade immunotherapy. The research, published in *Science Translational Medicine*, found that targeting this receptor with an approved compound, mirvetuximab soravtansine, can restore the cancer-killing efficacy of immunotherapy in mice. Colorectal cancer is the third most common cancer globally, but responses to immune checkpoint blockade treatments like anti-PD-1 have been limited, with only about 15% of patients experiencing significant benefits. CRC tumors often exhibit properties that hinder anti-tumor immunity, including defects in MHC-1 expression, which drives immune evasion. The study identified FOLR1 as a top negative regulator of immunotherapy response, with high expression predicting poor outcomes and enhanced cancer stemness. In vitro experiments showed that FOLR1 indirectly impaired the STAT1 signaling pathway and dampened MHC-1 activity, preventing CD8+ ...